MedTrace Logo

Vaccine Study for Surgically Resected Pancreatic Cancer

NCT00569387 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2020-05-28

No results posted yet for this study

Summary

To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.

Conditions

Interventions

BIOLOGICAL

HyperAcute(R)-Pancreatic Cancer Vaccine

100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months

Sponsors & Collaborators

  • NewLink Genetics Corporation

    lead INDUSTRY

Principal Investigators

  • Charles J. Link, M.D. · NewLink Genetics Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-03-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00569387 on ClinicalTrials.gov